tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS)

Molecular and Cellular Biochemistry

Volumn 283, Issue 1-2, 2006, Pages 159-167

  Morré, D James ^a   Morre, Dorothy M ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Aspirin; Cancer; Celecoxib; Cyclooxygenase; ECTO NOX; Hydroquinone (NADH) oxidase: tNOX; NADH oxidase; Non steroidal anti inflammatory drugs (NSAIDS); Rofecoxib; Tumor associated hydroquinone (NADH) oxidase

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CELL SURFACE PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; ROFECOXIB; ANTINEOPLASTIC AGENT; TUMOR ASSOCIATED NADH OXIDASE; TUMOR PROTEIN; TUMOR-ASSOCIATED NADH OXIDASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CARCINOMA CELL; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM CELL; EVIDENCE BASED MEDICINE; GENE TARGETING; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; TUMOR GROWTH; BREAST; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IC 50; METABOLISM;

MINK CELL FOCUS-FORMING VIRUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; NADH, NADPH OXIDOREDUCTASES; NEOPLASM PROTEINS; TRANSFECTION;

EID: 33645776988     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-2568-z     Document Type: Article

References (35)

1. Dannenberg AJ, Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 4: 431-436, 2003
2. Moore BC, Simmons DL: COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Curr Med Chem 7: 1131-1144, 2000
3. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002
4. Rahme E, Barkun AN, Toubouti Y, Bardou M: The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125: 404-412, 2003
5. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hia T: Overexpression of COX-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569, 2001
6. Neufang G, Furstenberger G, Heidt M, Marks F, Muller-Decker K: Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA 98: 7629-7634, 2001
7. Kazanov D, Dvory-Sobol H, Pick M, Liberman E, Strier L, Choen-Noyman E, Deutsch V, Kunik T, Arber N: Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Can Res 10: 267-271, 2004
8. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ: Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Can Res 11: 1999-2007, 2005
9. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033, 2002
10. Morré DJ, Morré DM: Cell surface NADH oxidase (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Rad Res 37: 759-808, 2003
11. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner RH, Provenzano EK, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985
12. Morré DJ: NADH oxidase: a multifunctional ectoprotein of the eukaryotic cell surface. In: H. Asard, A. Bérczi, R. Caubergs (eds). Plasma membrane redox systems and their role in biological stress and disease. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998 pp. 121-156
13. Morré DJ, Morré DM: Synergistic Capsicum-tea mixtures with anticancer activity. J Pharm Pharmacol 55: 987-994, 2003
14. Sedlak D, Morre DM, Morré DJ: A drug-unresponsive and protease-resistant CNOX protein from human sera. Arch Biochem Biophys 386: 106-116, 2001
15. Lin YL, Juan IM, Chen YL, Liang YC, Lin JK: Composition of polyphenols in fresh tea leaves and associations of their oxygen-radical-absorbing capacity with antiproliferative actions in fibroblast cells. J Agric Food Chem 44: 1387-1394, 1996
16. Morré DJ, Chueh P-J, Morré DM: Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA 92: 1821-1835, 1995
17. North GL: Celecoxib as adjunctive therapy for treatment of colorectal cancer. An Pharmacother 35: 1638-1643, 2001
18. Chueh P-J, Kim C, Cho N, Morré DM, Morré DJ: Molecular cloning and characterization of a tumor-associated, growth-related and time-keeping hydroquinone (NADH) oxidase (NOX) of the HeLa cell surface. Biochemistry 41: 3732-3741, 2002
19. Chueh P-J, Wu L-Y, Morré DM, Morré DJ: TNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-) epigallocatechin gallate. BioFactors 20: 249-263, 2004
20. Morré DJ. Bridge A, Wu L-Y, Morré DM: Epigallocatechin gallate inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Biochem Pharmacol 60: 937-946, 2000
21. Morré DM, Morré DJ: Mechanism of killing of HeLa cells by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)- N′ -(4-chlorophenyl)urea (LY181984). Protoplasma 184: 188-195, 1995
22. Tang X, Tian Z, Chueh P-J, Chen S, Morré DM, Morré DJ: Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface. In preparation
23. Morré DJ, Morré DM, Su H, Cooper R, Chang J, Janle EM: Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). Pharmcol Toxicol 92: 234-241, 2003
24. Wu KK: Aspirin and other cyclooxygenaseNinhibitors: new therapeutic insights. Semin Vasc Med 3: 107-112, 2003
25. Ochi T, Goto T: Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis. Br J Pharmacol 135: 782-788, 2002
26. Szewczuk LM, Forti L, Stivala LA, Penning TM: Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279: 22727-22737, 2004
27. Gerhauser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, Knauft J, Neumann I, Scherf HR, Frank N, Bartsch H, Becker H: Cancer chemopreventive activity of xanthohumol, a natural product derived from hops. Mol Cancer Ther 1: 959-969, 2002
28. Stevens JF, Page JE: Xanthohumol and related prenylflavonoids from hops and beer. Phytochemistry 65: 1317-1330, 2004
29. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R: Genetic disruption of Ptgs -1, as well as of Ptgs -2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60: 4705-4708, 2000
30. SubbaramaiahAK, Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003
31. Williams CS, Tsujii M, Reese J, Dey SK, DuBoise RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594, 2000
32. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002
33. Bosett C, Gallus S,ALa Vecchia C: Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 11: 535-542, 2002
34. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, Schrader H, Bastian A, Schmidt WE, Schmitz F: The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 32: 838-846, 2002
35. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E: Aspirin use and mortality from cancer in a prospective cohort study Anticancer Res 24: 3177-3184, 2004